Zedde, M.; Losa, M.; Donniaquio, A.; Gandoglia, I.; Sette, M.D.; Roccatagliata, L.; Piazza, F.; Pardini, M.; Pascarella, R.
Drug-Induced Amyloid-Related Imaging Abnormalities: A Neurovascular Perspective on Risk Assessment. Pharmaceuticals 2026, 19, 579.
https://doi.org/10.3390/ph19040579
AMA Style
Zedde M, Losa M, Donniaquio A, Gandoglia I, Sette MD, Roccatagliata L, Piazza F, Pardini M, Pascarella R.
Drug-Induced Amyloid-Related Imaging Abnormalities: A Neurovascular Perspective on Risk Assessment. Pharmaceuticals. 2026; 19(4):579.
https://doi.org/10.3390/ph19040579
Chicago/Turabian Style
Zedde, Marialuisa, Mattia Losa, Andrea Donniaquio, Ilaria Gandoglia, Massimo Del Sette, Luca Roccatagliata, Fabrizio Piazza, Matteo Pardini, and Rosario Pascarella.
2026. "Drug-Induced Amyloid-Related Imaging Abnormalities: A Neurovascular Perspective on Risk Assessment" Pharmaceuticals 19, no. 4: 579.
https://doi.org/10.3390/ph19040579
APA Style
Zedde, M., Losa, M., Donniaquio, A., Gandoglia, I., Sette, M. D., Roccatagliata, L., Piazza, F., Pardini, M., & Pascarella, R.
(2026). Drug-Induced Amyloid-Related Imaging Abnormalities: A Neurovascular Perspective on Risk Assessment. Pharmaceuticals, 19(4), 579.
https://doi.org/10.3390/ph19040579
